Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, announced today that the Japanese Patent Office issued two patents on the core technology that may be used for therapeutic applications and in the Company's breast cancer risk assessment test, the Mammastatin Serum Assay (MSA).
More...